New therapeutic approaches for SLE and lupus-like syndromes would be better directed on modifying Foxp3 expression by interfering with TLR7 activation or by blocking downstream effector cytokines such as IL-6. Here, TLR7 is linked to drug-induced lupus erythematosus.